References
- J. Warkany. Aminopterin and methotrexate: folic acid deficiency. Teratology. 17: 1978; 353–358.
- H.M. Evans. Congenital skeletal anomalies resulting from transitory maternal folic acid deficiency. Anatomical Record. 115: 1953; 303–306.
- A. Giroud. Anomalies provoquées chez le foetus en l'absence d'acide folique. Archives Françaises de Pédiatrie. 8: 1995; 648–656.
- J.B. Thiersch. Action of 4-aminopteroylglutamin acid on the early pregnancy of rats and mice. Federation Proceedings. 9: 1950; 346.
- J.B. Thiersch. The control of reproduction in rats with the aid of antimetabolites and early experiences with antimetabolites as abortifacient agents in man. Acta Endocrinologica. 28: 1956; 37–45.
- M. Brandner. Foetopathie due à l'aminoptérine avec stenose congénitale de l'espace médullaire des os tubulaires longs. Annales de Radiologie. 12: 1969; 703–710.
- D.J. Emerson. Congenital malformations due to attempted abortion with Aminopterin. American Journal of Obstetrics and Gynecology. 84: 1962; 356–357.
- C. Goetsch. An evaluation of aminopterin as an abortifacient. American Journal of Obstetrics and Gynecology. 83: 1962; 1474–1477.
- E.D. Hibbard. Folic acid metabolism and human embryopathy. Lancet. 1: 1965; 1254.
- H.J. Meltzer. Congenital anomalies due to attempted abortion with 4- aminopteroglutamic acid. Journal of American Medical Association. 161: 1956; 1253.
- E.B. Shaw. Aminopterin-induced fetal malformation: survival of infant after attempted abortion. American Journal of Diseases in Children. 115: 1968; 477–482.
- E.B. Shaw. Fetal damage due to maternal aminopterin ingestion. American Journal of Diseases in Children. 124: 1972; 93–94.
- A. Milsunsky. Methotrexate-induced congenital malformations. Journal of Pediatrics. 72: 1968; 790–795.
- Physicians' Desk Reference. Methotrexate. 1996; Medical Economics Company: Montvale, NJ, 1275–1279.
- E. Schiff. Pharmacokinetics of methotrexate after local tubal injection for conservative treatment of ectopic pregnancy. Fertility and Sterility. 57: 1992; 688–690.
- H. Fernandez. Treatment of unruptured tubal pregnancy with methotrexate: pharmacokinetic analysis of local versus intramuscular administration. Fertility and Sterility. 62: 1994; 943–947.
- P. Bourget. Pharmacocinétique du méthotrexate et réponse clinique associée dans le traitement medical des grossesses extra-utérines. Thérapie. 46: 1991; 399–403.
- H.R. Powell. Methotrexate-induced congenital malformations. Medical Journal of Australia. 2: 1971; 1076–1077.
- E.M. Diniz. Efietos sobre o concepto do methotrexate (ametopterine) administrado a mac. Apresentaçao de caso. Revista do Hospital das Clinicas; Faculdade de Medicine a Universidade de Sao Paulo. 33: 1978; 286–290.
- J. Warkany. Aminopterin and methotrexate: folic acid deficiency. Teratology. 17: 1978; 353–358.
- M. Feldkamp. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology. 47: 1993; 533–539.
- A.E. Donnerfeld. Methotrexate exposure prior to and during pregnancy. Teratology. 49: 1994; 79–81.
- R.D. Kozlowski. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. American Journal of Medicine. 88: 1990; 589–592.
- K.A. Higgins. Treatment of persistent trophoblastic tissue after salpingostomy with methotrexate. Fertilility and Sterility. 45: 1986; 427–428.
- J.J. Stangel. Recent techniques for the conservative management of tubal pregnancy: surgery, laparoscopy and medicine. Journal of Reproductive Medicine. 31: 1986; 98–101.
- H. Fernandez. The place of methotrexate in the management of interstitial pregnancy. Human Reproduction. 6: 1991; 302–306.
- T.G. Stovall. Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases. Obstetrics and Gynecology. 77: 1991; 749–753.
- M.V. Sauer. Nonsurgical management of unruptured ectopic pregnancy: an extended clinical trial. Fertility and Sterility. 48: 1987; 752–755.
- S. Kooi. Treatment of tuba] pregnancy by local injection of methotrexate after adrenalin injection into the mesosalpinx: a report of 25 patients. Fertility and Sterility. 54: 1990; 580–584.
- K. Ichinoe. Nonsurgical therapy to preserve oviduct function in patients with tubal pregnancies. American Journal of Obstetrics and Gynecology. 156: 1987; 484–487.
- S.J. Ory. Conservative treatment of ectopic pregnancy with methotrexate. American Journal of Obstetrics and Gynecology. 156: 1986; 1299–1306.
- I.A. Rodi. The medical treatment of unruptured ectopic pregnancy with methotrexate and citovorum rescue: preliminary experience. Fertility and Sterility. 46: 1986; 811–813.
- T.G. Stovall. Outpatient chemotherapy of unruptured ectopic pregnancy. Fertility and Sterility. 51: 1989; 435–438.
- H. Zakuti. Management of tubal pregnancy with methotrexate. British Journal of Obstetrics and Gynaecology. 96: 1989; 725–728.
- H. Fernandez. Conservative management of ectopic pregnancy: prospective randomized clinical trial of methotrexate versus prostaglandinsulprostone by combined transvaginal and systemic administration. Fertility and Sterility. 55: 1991; 746–750.
- H. Fernandez. Methotrexate treatment of ectopic pregnancy: 100 cases treated by primary transvaginal injection under sonographic control. Fertility and Sterility. 59: 1993; 773–777.
- M. Goldenberg. Methotrexate therapy of tubal pregnancy. Human Reproduction. 8: 1993; 660–666.
- A. Schoenfeld. Methotrexate pneumonitis in nonsurgical treatment of ectopic pregnancy. Obstetrics and Gynecology. 80: 1992; 520–521.
- C. Floridon. Methotrexate treatment of ectopic pregnancy. Acta Obstetricia et Gynecologica Scandinavica. 73: 1994; 746–752.
- J.D. Isaacs. Life-threatening neutropenia following methotrexate treatment of ectopic pregnancy: A report of two cases. Obstetrics and Gynecology. 88: 1996; 694–696.
- K. Buckshee. A new nonsurgical technique for termination of intrauterine pregnancy associated with large multiple uterine leiomyomatas. International Journal of Gynaecology and Obstetrics. 37: 1992; 297–299.
- M.D. Creinin. Methotrexate and misoprostol for early abortion. Contraception. 48: 1993; 339–348.
- M.D. Creinin. Methotrexate for abortion at 42 days gestation. Contraception. 48: 1993; 519–525.
- M.D. Creinin. Methotrexate and misoprostol for abortion at 57–63 days gestation. Contraception. 50: 1994; 511–514.
- M.D. Creinin. Methotrexate and misoprostol vs misoprostol alone for early abortion. JAMA. 272: 1994; 1190–1195.
- M.D. Creinin. A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. American Journal of Obstetrics and Gynecology. 173: 1995; 1578–1584.
- E.A. Schaff. Combined methotrexate and misoprostol for early induced abortion. Archives of Family Medicine. 4: 1995; 774–779.
- R.V. Hausknecht. Methotrexate and misoprostol to terminate early pregnancy. New England Journal of Medicine. 333: 1995; 537–540.
- E.R. Wiebe. Abortion induced with methotrexate and misoprostol. Canadian Medical Association Journal. 154: 1996; 165–170.
- P.S. Schonhofer. Brazil: misuse of misoprostol as an abortifacient may induce malformations. Lancet. 337: 1991; 1534–1535.
- W. Fonseca. Misoprostol and congenital malformations. Lancet. 338: 1991; 56.
- W. Fonseca. Congenital malformation of the scalp and cranium after failed first trimester abortion attempt with misoprostol. Cl9nical Dysmorphology. 2: 1993; 76–80.
- L. Schüler. Teratogenicity of misoprostol. Lancet. 339: 1992; 437.